Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

High frequency ultrasonography and HR-MRI can help identify hair shedding causes like inflammation and fibrosis. The conversation discusses the potential of using these technologies to evaluate treatments like Verteporfin for hair regeneration.

Injectable GHK-CU and BPC157 were discussed for hair loss, but users did not notice significant hair changes. BPC157 was noted to help with shoulder issues.

Users discussed using GHK-Cu and AHK-Cu peptides with microneedling for hair loss, noting some small changes after 7-8 weeks. They mentioned continued shedding but no widening of the part.

The conversation discusses the synthesis and potential use of JXL069 and PP405 for hair loss treatment, with skepticism about their effectiveness and concerns about safety. Users mention that JXL069 has shown no results in hair growth, and there is confusion about its identity and effectiveness compared to PP405.

AHK-Cu peptide is considered better than GHK-Cu for hair growth. The user is seeking recommendations for trusted AHK-Cu peptide brands with third-party testing.

PP405, a topical treatment, shows promise for hair growth by activating inactive follicles, with 66% of participants experiencing positive results. The treatment is well-tolerated and may proceed directly to Phase 3 trials, offering a potential alternative to minoxidil and finasteride.

Scientists at UCLA have developed a promising treatment for male pattern baldness using a molecule called PP405, which can potentially stimulate dormant hair follicles. Initial trials showed significant results within a week, but larger clinical trials are needed to confirm its efficacy and safety.

People are discussing early results of the grey market hair loss treatment PP405. They mention previous attempts with jxl069 and interest in PP30.

Protein's role in hair growth is complex, with specific amino acids like cysteine being crucial for effective hair growth. Users discussed using l-cysteine supplements, noting reduced hair loss and faster growth, though some experienced digestive issues.

BPC-157 is debated for hair loss, with some claiming it helps, but most agree there's no solid evidence for hair regrowth. Finasteride is mentioned as a common treatment, but results vary.

The conversation discusses the potential effectiveness and future results of the hair loss treatment pp405, with questions about its impact on different hair loss stages and areas. There is anticipation for phase 3 trial results to provide more data, and hope that pp405 could enhance hair transplant outcomes.

Pelage, backed by Google Ventures, is seen as a promising company potentially finding a cure for hair loss using stem cell activation. There is skepticism and optimism among users, with some awaiting results from ongoing trials.

People are seeking updates on PP405, a hair loss treatment, with no new information available beyond old news and speculation about trial phases. A user shared concerns about hair shedding after using finasteride and minoxidil, with others suggesting it might be temporary shedding.

The conversation is about someone planning to start finasteride for hair loss and wanting to interpret pre-treatment blood panels to assess the risk of side effects like gynecomastia. They list various tests to measure hormone levels and other health indicators.

PP405 is considered a potential new treatment for hair loss, compared to finasteride and minoxidil. There is skepticism about its effectiveness in humans, with anticipation for more information from an upcoming conference.

PP405's effectiveness in increasing hair density is questioned due to a small sample size, despite investment from Google Ventures. Users express skepticism and suggest waiting for more conclusive results.

Whey protein may slightly increase hair loss in men with androgenetic alopecia (AGA) due to elevated IGF-1 and testosterone levels, but the effect is minimal compared to treatments like finasteride and dutasteride. Many users argue that whey protein's impact on hair loss is negligible and that maintaining a healthy lifestyle is more important.

KX-826 users report increased shedding, with some experiencing more shedding at higher concentrations. Users are discussing where to purchase the product.

GHK-Cu peptide injections are discussed for hair growth, but users report mixed results and suggest focusing on DHT management first. Some users combine GHK-Cu with treatments like Minoxidil and Dutasteride, but emphasize its benefits for skin rather than hair.

PP405 is progressing to Phase 2b trials, with results expected in late 2025 or early 2026, and potential Phase 3 trials in 2026. Some users experienced side effects from finasteride and are hopeful for PP405 as an alternative treatment.

Gizzela is unsure about the dosage and frequency of copper peptides and asks if they can be used with Stemoxydine. They seek advice on applying these treatments together.

Iontophoresis and sonophoresis can enhance drug delivery into the scalp. Combining these methods may improve the effectiveness of topical treatments like dutasteride and certain peptides.

The user mixed Pyrilutamide with a KB solution and noticed some undissolved powder, questioning if more shaking or liquid is needed. They use Pyrilutamide from Anagenic.

Amino acids, particularly Cysteine, are important for hair growth and may be lacking in a normal diet. Using a protein powder that includes these amino acids can help improve hair growth and strength.

PP405 is a new hair loss treatment that may outperform minoxidil and finasteride by growing thick hair in bald areas within four weeks. Its release is expected around 2028, but concerns about its long-term efficacy and cost remain.

PP405 is a new hair loss treatment advancing quickly in trials, generating excitement and skepticism about its effectiveness and marketing claims. Some see it as a potential alternative to minoxidil and finasteride, but concerns about long-term effects and the need for DHT blockers persist.

Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.

A user created a tracker for hair loss treatments in clinical development, including compounds like Dermaliq, RU58841, and Pyrilutamide. The tracker updates with new information and allows filtering by conditions like androgenetic alopecia (AGA) and alopecia areata (AA).

Lactic acid is not effective for hair growth when applied topically. JXL069, finasteride, and minoxidil are suggested as alternative treatments.

Suvomipic, previously known as PP405, is progressing to Phase 3 trials for hair loss treatment. Its effectiveness compared to existing treatments like Minoxidil and Finasteride is still uncertain.